SEB Asset Management AB purchased a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 232,416 shares of the company’s stock, valued at approximately $24,497,000.
A number of other institutional investors also recently modified their holdings of the company. Farther Finance Advisors LLC increased its position in shares of Protagonist Therapeutics by 110.6% during the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after buying an additional 156 shares during the period. Greenline Wealth Management LLC acquired a new position in Protagonist Therapeutics in the fourth quarter valued at $27,000. Osaic Holdings Inc. lifted its holdings in Protagonist Therapeutics by 79.5% in the second quarter. Osaic Holdings Inc. now owns 1,185 shares of the company’s stock valued at $65,000 after buying an additional 525 shares during the period. Hantz Financial Services Inc. boosted its position in Protagonist Therapeutics by 222.4% during the fourth quarter. Hantz Financial Services Inc. now owns 951 shares of the company’s stock valued at $83,000 after acquiring an additional 656 shares during the last quarter. Finally, Canton Hathaway LLC bought a new stake in Protagonist Therapeutics during the fourth quarter valued at $87,000. 98.63% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
PTGX has been the subject of several research analyst reports. Wall Street Zen lowered Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Wedbush upped their target price on Protagonist Therapeutics from $112.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $110.00 target price on shares of Protagonist Therapeutics in a research note on Wednesday, May 6th. Johnson Rice set a $165.00 target price on Protagonist Therapeutics in a report on Friday. Finally, Citizens Jmp boosted their price target on Protagonist Therapeutics from $120.00 to $137.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $123.00.
Protagonist Therapeutics Stock Performance
Shares of PTGX opened at $140.91 on Monday. The stock has a 50 day moving average price of $113.50 and a two-hundred day moving average price of $99.72. The firm has a market capitalization of $9.06 billion, a P/E ratio of -77.85 and a beta of 1.79. Protagonist Therapeutics, Inc. has a 52 week low of $50.49 and a 52 week high of $141.10.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.50) by $0.55. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%.The firm had revenue of $56.37 million during the quarter, compared to the consensus estimate of $11.70 million. On average, equities analysts forecast that Protagonist Therapeutics, Inc. will post 2.93 earnings per share for the current year.
Insider Buying and Selling
In other Protagonist Therapeutics news, Director William D. Waddill sold 9,000 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $117.94, for a total transaction of $1,061,460.00. Following the transaction, the director directly owned 7,825 shares in the company, valued at approximately $922,880.50. This trade represents a 53.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bryan Giraudo sold 6,000 shares of Protagonist Therapeutics stock in a transaction on Friday, May 8th. The stock was sold at an average price of $100.00, for a total transaction of $600,000.00. Following the transaction, the director directly owned 31,825 shares in the company, valued at $3,182,500. This represents a 15.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 161,130 shares of company stock worth $16,355,220. 5.19% of the stock is owned by corporate insiders.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.
Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.
Read More
- Five stocks we like better than Protagonist Therapeutics
- Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
- Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet
- Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises
- 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks
Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report).
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
